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The prostate tumor suppressor NKX3.1 augments
response to DNA damage and enhances survival
after DNA damage. Within minutes of DNA damage,
NKX3.1 undergoes phosphorylation at tyrosine 222,
which is required for a functional interaction with
ataxia telangiectasia mutated (ATM) kinase. NKX3.1
binds to the N-terminal region of ATM, accelerates
ATM activation, and hastens the formation of
ghistone2AX. NKX3.1 enhances DNA-dependent
ATM kinase activation by both the MRN complex
and H2O2 in a DNA-damage-independent manner.
ATM, bound to the NKX3.1 homeodomain, phos-
phorylates NKX3.1, leading to ubiquitination and
degradation. Thus, NKX3.1 and ATM have a func-
tional interaction leading to ATM activation and
then NKX3.1 degradation in a tightly regulated DNA
damage response specific to prostate epithelial
cells. These findings demonstrate a mechanism for
the tumor-suppressor properties of NKX3.1, demon-
strate how NKX3.1 may enhance DNA integrity in
prostate stem cells andmay help to explain how cells
differ in their sensitivity to DNA damage.
INTRODUCTION
To combat threats imposed by DNA damage, cells have evolved
the DNA damage response to detect newly created genetic
lesions, signal their presence, and initiate repair (Ciccia and
Elledge, 2010; Jackson and Bartek, 2009). Cells that are defec-
tive in these mechanisms display heightened sensitivity to
DNA-damaging agents and in some instances are prone to can-
cer. It is widely appreciated that the prostatic epithelium is sub-
ject to DNA damage due to inflammation in the aging prostate
gland (Nelson et al., 2003; Shen and Abate-Shen, 2010). We
have shown that the prostate gatekeeper suppressor NKX3.1516 Cell Reports 4, 516–529, August 15, 2013 ª2013 The Authorsplays a significant role in protecting against DNA damage and
promoting DNA repair in the prostate, while its loss of expression
predisposes the prostatic epithelium to DNA damage (Bowen
and Gelmann, 2010).
NKX3.1 is a haploinsufficient prostate cancer suppressor
protein that has reduced expression in the majority of human
primary prostate cancers (Asatiani et al., 2005). NKX3.1 downre-
gulation also likely predisposes to the formation of invasive pros-
tate cancer, since decreased expression is seen in premalignant
lesions and prostatic intraepithelial neoplasia (PIN) (Asatiani
et al., 2005; Bethel et al., 2006). During prostate cancer progres-
sion, there is progressive loss of NKX3.1 expression, suggesting
that there is selective pressure against expression of this sup-
pressor protein (Bowen et al., 2000). NKX3.1 downregulation
results from genetic loss, DNA methylation, or both, and in
addition, NKX3.1 turnover is accelerated by ubiquitination and
proteasomal degradation triggered by cellular exposure to in-
flammatory cytokines (Asatiani et al., 2005; Markowski et al.,
2008). In this way, regions of inflammatory atrophy may cause
both downregulation of NKX3.1 and oxidative damage that
accompanies inflammation (Bethel et al., 2006). Inflammation
is known to predispose surrounding cells to oxidative damage
and, as a result, cause procarcinogenic mutations (Murata
et al., 2012). In fact, in regions of bacterial prostatitis, another in-
flammatory risk factor for prostate cancer, NKX3.1 expression
was also seen to be decreased (Khalili et al., 2010).
The DNA damage response may be activated directly by
agents that can induce DNA damage or by the presence of intra-
cellular free oxygen radicals (Ciccia and Elledge, 2010; Jackson
and Bartek, 2009). An early step in the DNA damage response is
the rapid accumulation of damage-signaling proteins at the
damage site, corresponding to the sensor complex of the pro-
teinsMRE11, Rad50, and NBS1 (MRN complex) (Bekker-Jensen
et al., 2006). This is followed by recruitment of the transducer
proteins MDC1 and 53BP1. Interestingly, 53BP1 is both an inter-
acting protein of and substrate for ataxia telangiectasia mutated
(ATM), and is used experimentally as an index of ATM activation.
ATM is one of three DNA-dependent PI3 kinase-like proteins
(the others being DNA-dependent protein kinase [DNA-PK] and
ataxia telangiectasia and Rad3-related [ATR]) that mediate the
early response to DNA damage (for review, see Kurz and Lees-
Miller, 2004). ATM phosphorylates the histone variant H2AX
and downstream effectors, including the Chk1 and Chk2 cell-
cycle kinases (Bartek and Lukas, 2003; Lee and Paull, 2004,
2005; Paull and Lee, 2005). Thus, ATM serves as a key trans-
ducer of DNA damage signals in mammalian cells being acti-
vated in part by the MRN complex bound to double-stranded
breaks to signal through phosphorylation of H2AX and a myriad
of other substrates (Fernandez-Capetillo et al., 2004; Kurz and
Lees-Miller, 2004). Furthermore, ATM also reacts to levels of
reactive oxygen species and may act as a cellular sensor for
oxidative potential (Ditch and Paull, 2011).
Upon activation by DNA damage, ATM undergoes autophos-
phorylation at serine 1981 (S1981) and three other (S/T)Q sites
favored for ATM substrates (for review, see Ditch and Paull,
2011). ATM also is activated by oxidative stress independently
of DNA damage (Guo et al., 2010b). Since oxidative stress may
be a major source of DNA damage in the prostate, ATM may
play a major role in protecting prostate epithelial cells from
DNA damage induced by oxidative stress. ATM undergoes
extensive phosphorylation after DNA damage, including phos-
phorylation at S1981 that is used as an experimental marker
for ATM activation. However, missense mutation of several of
the ATM phosphorylation sites in mice, including the site analo-
gous to S1981, demonstrated that they were not essential for at
least some aspects of ATM activation (Daniel et al., 2008).
We have previously shown that NKX3.1 enhances cell survival
after DNA damage and that NKX3.1 enhances the DNA damage
response by increasing ATM activation and gH2AX accumula-
tion at the damage site (Bowen and Gelmann, 2010). We now
demonstrate that the importance of NKX3.1 to the stem cell
may be via enhancement of the DNA damage response medi-
ated by ATM.
RESULTS
NKX3.1 Affects the ATM Response to DNA Damage
NKX3.1 colocalizes with gH2AX to sites of DNA damage induced
by laser microirradiation (LMI) (Bowen and Gelmann, 2010).
Moreover, NKX3.1 can be found bound at a site of double-strand
DNA breakage, as shown by chromatin immunoprecipitation
(ChIP) of NKX3.1 at a DNA cleavage site introduced into 293T
cells and cut by the I-SceI restriction endonuclease (Figure 1A).
Changing the expression level of NKX3.1 either by small inter-
fering RNA (siRNA) knockdown in LNCaP cells or by exogenous
expression of NKX3.1 in PC-3 cells affected the cells’ acute re-
sponses to DNA damage. Within 5 min of DNA damage induced
by LMI, the accumulation of ATM, phosphorylated ATM at S1981
(pATM(S1981)), and gH2AX at DNA damage sites was affected
by changes in NKX3.1 expression levels (Figure 1B). Quantitation
of gH2AX and pATM(S1981) at the DNA damage site at 1 min in-
tervals showed that NKX3.1 expression affected both the rate
and the magnitude of protein accumulation (Figure S1A). We
confirmed the effects of NKX3.1 knockdown in the LNCaP(si471)
cells by using si3098, another NKX3.1 silencing construct that
we previously described (Bowen and Gelmann, 2010), to ensure
that the effect on NKX3.1 downregulation was not unique to asingle siRNA, thus decreasing the likelihood of off-target effects
(Figure S1B). In contrast to the response of ATM, we saw little
effect of NKX3.1 expression on the intracellular localization of
ATR (Figure 1B, bottom panels). Whereas ATM localization to
the laser wound was enhanced >3-fold by the expression of
NKX3.1 in PC-3 cells, ATR localization was increased by <2-
fold. We previously demonstrated that enhanced phosphoryla-
tion of the ATR substrate CHK1 occurred in the presence of
NKX3.1, but the ATR activation followed ATM phosphorylation
chronologically (Bowen and Gelmann, 2010). The effect of
NKX3.1 expression on gH2AX localization at DNA damage sites
was mediated at least in part by ATM, since the ATM inhibitors
Ku55933 and caffeine both diminish the effect of NKX3.1 on
H2AX phosphorylation, thus implicating an interaction between
NKX3.1 and ATM as a mechanism whereby NKX3.1 affects the
DNA damage response (Figure 1C). A very similar response
was seen when LNCaP(siLuc) and LNCaP(si471) cells were
exposed to 10Gy g-irradiation (Figure 1D). Furthermore, ATM
phosphorylation was also demonstrated in situ after g-irradiation
of LNCaP cells (Figure S1C). Moreover, knockdown of NKX3.1
in LNCaP cells was shown using two different interfering
RNA sequences, thus decreasing the likelihood of off-target
effects by the siRNAs in this experimental system. The opposite
effect on the DNA repair response was seen in PC-3 cells engi-
neered to express NKX3.1 (Figure 1C).
To determine whether NKX3.1 directly affected ATM activity,
we performed an in vitro assay using affinity-purified, epitope-
tagged ATM that was incubated with purified P53 and NKX3.1.
In vitro phosphorylation of P53 at serine 15 (S15), a known target
site for ATM kinase (Khanna et al., 1998), was enhanced in cor-
relation with the amount of NKX3.1 added to the reaction that
included tagged ATM (Figure 2A). However, there was no effect
of NKX3.1 on pP53(S15) when the experiment was reproduced
with a kinase-inactivated ATM expression construct (Figure 2B).
Addition of NKX3.1 to an in vitro kinase reaction also decreased
the concentration threshold at which ATM activity was seen (Fig-
ure 2C). As predicted by the in vitro reconstitution experiments,
P53 phosphorylation was reduced by NKX3.1 knockdown in
LNCaP cells subjected to irradiation and probed for Flag-tagged
ATM, and also in heterologous 293T cells expressing both Flag-
ATM and MYC-NKX3.1 (Figure 2D). NKX3.1 also activated ATM
kinase in vitro in an ATM activation reaction reconstituted with
purified reaction components (Lee and Paull, 2005). Purified re-
combinant NKX3.1 enhanced the activation of ATM by the MRN
complex and DNA (Figure 2E). Interestingly, mutations of the
homeodomain that inhibited binding of NKX3.1 to its cognate
DNA binding domain, T179A (Gelmann et al., 2002) and N174Q
(Bowen and Gelmann, 2010), did not interfere with the protein-
protein interaction between NKX3.1 and ATM even though these
mutations had attenuated the effect of NKX3.1 on ATM in whole
cells (Bowen and Gelmann, 2010). Activation of ATM by oxida-
tion was enhanced substantially more by NKX3.1 than was acti-
vation by theMRNcomplex (Guo et al., 2010a, 2010b; Figure 2F).
Thus, purified NKX3.1 has a direct effect on ATM activation
in vitro by both double-stranded DNA breaks and H2O2. In
LNCaP cells exposed to H2O2, we observed that the presence
of NKX3.1 enhanced ATM phosphorylation as compared with
LNCaP cells with NKX3.1 knockdown (Figure 2G).Cell Reports 4, 516–529, August 15, 2013 ª2013 The Authors 517
Figure 1. NKX3.1 Affects Response to DNA
Damage of ATM
(A) 293T cells engineered with a single I-SceI
cleavage site were transfected with an I-SceI
expression vector with or without expression of
NKX3.1. ChIP analysis of sequences of the GFP
coding region at the cleavage site showed accu-
mulation of NKX3.1.
(B) LNCaP cells stably transfected with control
or NKX3.1 knockdown lentiviral vector (Bowen
and Gelmann, 2010) or PC-3(pcDNA3) and PC-
3(NKX3.1) stable cell lines were pretreated with
10 mM of BrdU overnight and 10 mg/ml of Hoechst
33258 dye for 30 min. Cells were exposed to LMI
at power 36, focus 61, speed 20, and fixed 2–5min
after irradiation. Immunofluorescent detection of
proteins was done as indicated on the left. An
immunoblot demonstrating expression of NKX3.1
in the target cell lines is shown.
(C) LNCaP and PC-3 cells engineered for NKX3.1
knockdown or expression were treated with 10
mJ/cm2 UV irradiation and additionally pretreated
with either 10 mM Ku55933 or 2 mM caffeine for
30 min. Cells were pretreated with BrdU and
Hoechst 33258 dye as above prior to UV irradia-
tion and harvested after 10 min for immunoblot-
ting. The presence of gH2AX in LNCaP cells
treated with Ku55933 may be due to phosphory-
lation by ATR, DNA-dependent protein kinase, or
other enzymes.
(D) LNCaP(siLuc) and LNCaP(si471) cells were
pretreated as in (C) prior to irradiation with 10 Gy.
Cells were harvested after 10 min for immuno-
blotting.
See also Figure S1.We also asked whether NKX3.1 binding to ATM was favored
by ATM phosphorylation that resulted from ATM activation.
ATM is a homodimer in the inactive state and is dissociated
upon activation after DNA damage by means of transphosphor-
ylation at S1981 (Bakkenist and Kastan, 2003). ATM undergoes
phosphorylation after DNA damage at a number of other
residues as well. We observed increasing levels of ATM phos-
phorylation at S1981 during the first 20 min after DNA damage
(Figure 2H, left panel). In reciprocal pull-down experiments,
increasing amounts of NKX3.1 were seen to associate with
ATMat 10 and 20min after induction of DNAdamage (Figure 2H).
The data suggest that pATM was a preferred binding partner for
NKX3.1, suggesting that NKX3.1 affected ATM after dissociation
of the ATM homodimer by transphosphorylation.
ATM Binding Domain for NKX3.1
We studied the physical association between NKX3.1 and ATM
using glutathione S-transferase (GST)-fusion peptides that
together covered the entire length of the ATM protein. We found518 Cell Reports 4, 516–529, August 15, 2013 ª2013 The Authorsthat peptide GST-ATM-2 spanning amino
acids 250–522 interacted most strongly
with NKX3.1 (Figure 3A), and that this
interaction was observed with both
epitope-tagged NKX3.1 and native pro-tein expressed in LNCaP cells (Figure 3B). The ATM-2 peptide
includes the nuclear localization signal (NLS) located between
amino acids 385 and 388. To determine whether this region
was involved in NKX3.l binding, we performed a deletion anal-
ysis on the ATM-2 fragment. In GST pull-down experiments,
NKX3.1 was shown to bind to the region C-terminal to the
NLS at 431–490 (Figure 3C). The 431–490 region of ATM
involves a short segment of the HEAT repeat domain. To study
the interaction of NKX3.1 and ATM, we engineered an ATM
construct that lacked amino acids 431–490. In response to
DNA damage, this construct underwent S1981 phosphorylation
comparably to full-length ATM, and also displayed nuclear
localization that appeared to be similar to that of the full-length
protein (Figure 3D). Thus, we were able to perform experiments
comparing the activities of native ATM and ATM that lacked
NKX3.1 binding capability. Deletion of this 431–490 region abro-
gated the association of ATM with NKX3.1 and nullified the
effect of NKX3.1 on ATM phosphorylation after DNA damage
(Figure 3E).
Figure 2. NKX3.1 Activates ATM In Vitro
(A) Lysates from 293T cells transfected with
Flag-ATM were subjected to immunoprecipita-
tion with 30 ml of anti-Flag M2 agarose (Sigma)
for 1 hr. The Flag-ATM-bound beads were
preincubated with polyhistidyl-NKX3.1 for 30 min
and subsequently incubated with 1.5 mg
GST-P53. P53 was resolved by SDS-PAGE
and P53 phosphorylation was analyzed by
immunoblotting with monoclonal antibody to
phospho-P53(S15) (Cell Signaling). Levels of
His-NKX3.1 were demonstrated with NKX3.1
antiserum.
(B) Lysates of 293T cells were treated as in (A)
except that exogenous expression of Flag-ATM or
Flag-ATM-KD was engineered.
(C) Lysates of 293T cells transfected with different
amounts of Flag-ATM expression vector were
exposed to anti-Flag M2 agarose, which was
then washed and exposed to polyhistidine or
polyhistidylNKX3.1. After a 30 min incubation,
1 mg GST-P53 was added for 60 min at 30C.
The reaction mixtures were then analyzed by
immunoblotting as shown.
(D) LNCaP and 293T cells expressing the
indicated vectors were subjected to immuno-
precipitation and immunoblotting for pP53(S15).
The uniformity of transgene expression and
precipitation was confirmed by immunoblotting
with monoclonal ATM antibody and NKX3.1
antiserum.
(E) Kinase assay with dimeric ATM, MRN com-
plex, GST-P53 substrate, 10 ng linear DNA, and
256 ng NKX3.1 (wild-type [WT], T179A, and
T174Q), probed with antibody directed against
phosphoserine 15 of P53.
(F) Kinase assays with dimeric ATM, 0.7 mM
H2O2, and 4 and 16 ng of NKX3.1 (WT, T179A,
and T174Q), probed with antibody to phospho-
serine15 of P53.
(G) LNCaP(siLuc) and LNCaP(si471) cells were
exposed to 200 mM of H2O2 for the indicated
times. Cell extracts were processed for immuno-
blotting as shown.
(H) LNCaP cells were preloaded with BrdU and pretreated with Hoechst 33528 dye prior to UV irradiation with 10 mJ/cm2. Immunoprecipitation and
immunoblotting was performed with the indicated antibodies on cell lysates from cells harvested at the indicated times.Posttranslational Modification of NKX3.1 after DNA
Damage
NKX3.1 undergoes serine and threonine phosphorylation at a
number of sites that regulate protein turnover both in the steady
state and in response to a number of extracellular stimuli (Li et al.,
2006; Markowski et al., 2008). Because of its binding to ATM, we
also asked whether NKX3.1 underwent phosphorylation on (S/T)
Q sites, the preferred substrate targets for ATM kinase, thus
implicating NKX3.1 as an ATM substrate. NKX3.1 p(S/T)Q was
found to be increased at 30 min after irradiation and more so
at 60 min after irradiation (Figure 4A). In this immunodetection
experiment, we noted that the input NKX3.1 levels decreased
at both 30 and 60 min after DNA damage (Figure 4A, top panel).
We also observed that NKX3.1 underwent tyrosine phos-
phorylation within 5 min of DNA damage. (Tyrosine phosphoryla-
tion is described further below and in the data presented in
Figure 6.) We previously showed that NKX3.1 turnover is regu-lated by phosphorylation, and therefore, because of the
apparent correlation between serine/threonine phosphorylation
induced by DNA damage and NKX3.1 turnover, we further
examined the reduction of NKX3.1 levels suggested by the re-
sults in Figure 4A. UV exposure of LNCaP cells preloaded with
bromodeoxyuridine (BrdU) and treated with Hoechst 33258
dye resulted in decreased levels of NKX3.1 within 30 min (Fig-
ure 4B). The decline in NKX3.1 protein levels was prevented
by the proteasome inhibitor bortezomib, suggesting that DNA
damage resulted in ubiquitination and proteasomal degradation
of NKX3.1.
We investigated the relationship between NKX3.1 binding to
ATM, (S/T)Q site phosphorylation, and NKX3.1 degradation.
We expressed either ATM or ATM(D431–490) in 293T cells along
with MYC-NKX3.1. After UV exposure of cells preloaded with
BrdU and treated with Hoechst 33258 dye p(S/T)Q phosphoryla-
tion of NKX3.1 was seen in the presence of exogenous ATM,Cell Reports 4, 516–529, August 15, 2013 ª2013 The Authors 519
Figure 3. NKX3.1 Binding to ATM
(A) GST fusion proteins from different regions of
ATM as shown in the upper panel were produced
and resolved on SDS-PAGE stained with
Coomassie blue. A pull-down assay was per-
formed with 20 ml of bead slurry containing
GST-ATM fusion peptides incubated with puri-
fied His-NKX3.1. Glutathione beads bound to
fusion protein were incubated, washed four times,
and subjected to immunoblotting with NKX3.1
antiserum.
(B) Lysate from 293T cells expressing MYC-
NKX3.1 or LNCaP cells was subjected to GST
pull-down with the four fusion peptides as
indicated. GST-alone control lanes are shown as
indicated.
(C) GST-ATM-2 was sequentially deleted with
a Site-Directed Mutagenesis Kit (Stratagene).
PCR was performed as described by the manu-
facturer except with an extension time of
1.5 kb/min for 35 cycles. A GST pull-down assay
was performed with 200 mg of 293T(MYC-NKX3.1)
cell lysates.
(D) 293T cells engineered to express Flag-ATM
or Flag-ATM(D431-490) were preloaded with
BrdU and pretreated with Hoechst 33258 dye
prior to exposure to 10 mJ/cm2 UV. Cell
lysates were subjected to immunoprecipitation
and immunoblotting as shown. Also, in the
lower panels, expression of nuclear Flag-ATM
constructs was demonstrated by immunofluo-
rescence.
(E) 293T cells engineered to express MYC-
NKX3.1 and Flag-ATM constructs were preloaded
with BrdU and pretreated with Hoechst 33258
dye prior to exposure to UV irradiation. The
cells were harvested 10 min after UV exposure.
Immunoprecipitations were performed with Flag
antibody-bound agarose (Sigma) or MYC anti-
body (Santa Cruz) with a Catch-Release Kit
(Millipore). Immunoblots were probed with anti-
bodies as indicated.
See also Figure S2.but not exogenous ATM(D431–490) (Figure 4C, upper panel). In
Figure 4C the Flag epitope tag is used to demonstrate expres-
sion levels of the ATM transgenes. Moreover, reduced cellular
levels of MYC-NKX3.1 after UV exposure were seen in the
presence of ATM, but not ATM(D431–490) (Figure 4C, immuno-
blots in lower panel), thus demonstrating a correlation among
NKX3.1 binding to ATM, (S/T)Q phosphorylation, and NKX3.1
degradation after UV exposure. A similar effect was seen on
MYC-NKX3.1 when endogenous ATM in 293T cells was knocked520 Cell Reports 4, 516–529, August 15, 2013 ª2013 The Authorsdown with ATM siRNA (Figure 4D). ATM
knockdown was associated both with
reduced (S/T)Q phosphorylation of
NKX3.1 (Figure 4D, upper panel) and
with persistence of cellular NKX3.1 after
UV exposure (Figure 4D, lower panel). In
addition, we demonstrated that both
wild-type and kinase-dead (KD) ATM
associated with NKX3.1, but no (S/T)Qphosphorylation was seen with KD ATM, further demonstrating
that NKX3.1 is an ATM substrate (Figure 4E).
NKX3.1 Binding Domain for ATM
The suggestion that NKX3.1 was a substrate for ATM and that
NKX3.1 (S/T)Q phosphorylation led to NKX3.1 degradation
implied that ATM and NKX3.1 are involved in a regulatory loop
wherein NKX3.1 activates ATM, which in turn phosphorylates
NKX3.1, leading to its degradation. To explore this interaction
Figure 4. DNA Damage Induces Posttrans-
lational Modification of NKX3.1
(A) LNCaP cells pretreated with BrdU and Hoechst
33258 dye were harvested after 20 mJ/cm2 UV
irradiation. The 500 mg nuclear extract was incu-
bated with 4 mg of either IgG or goat anti-NKX3.1
antibody (Santa Cruz) together with Catch-
Release affinity ligand and columns. Eluted protein
was resolved by SDS-PAGE and immunoblotted
as shown.
(B) LNCaP cells were preloaded with BrdU and
pretreated with Hoechst 33258 dye with or
without 100 nM bortezomib for 1 hr prior to
exposure to 10 mJ/cm2 UV irradiation. Samples
were harvested and immunoblotting was done
with NKX3.1 antiserum.
(C) 293T cells were engineered to express Flag-
ATM constructs and MYC-NKX3.1. Cells were
preloaded with BrdU and pretreated with Hoechst
33258 dye prior to 10 mJ/cm2 UV exposure.
Cells were collected 60 min after UV exposure
and lysates were subjected to immunopre-
cipitation and immunoblotting (upper panel) or
immunoblotting (lower panel). For immunopre-
cipitation, bortezomib was added 30 min prior
to irradiation.
(D) The same as in (C) except that control and ATM
knockdown vectors were transfected into 293T
cells.
(E) 293T cells transfected with Flag-ATM expres-
sion plasmids and MYC-NKX3.1 were preloaded
with BrdU and pretreated with Hoechst 33258
dye prior to 10 mJ/cm2 UV irradiation. Cells were
harvested 30 min after irradiation. Lysates were
subjected to immunoprecipitation with MYC anti-
body and immunoblotting.further, we determined the domain(s) of NKX3.1 that are respon-
sible for ATM binding. Using GST-ATM-2 as a binding substrate
for epitope-tagged NKX3.1 peptides, we showed that the home-
odomain was both necessary and sufficient for binding (114–208
peptide in Figure 5A) and that the peptide N-terminal to the
homeodomain did not bind ATM-2 (1–123 peptide in Figure 5A).
In a more detailed deletion analysis of the NKX3.1 homeodo-
main, we observed that the regions spanning amino acids
131–140 and 151–160 both influenced ATM binding (Figure 5B).
These regions encompass T134 and are adjacent to T166, two
candidate TQ ATM phosphorylation sites.
When the native NKX3.1 was incrementally truncated from the
C-terminal end, we observed a marked reduction in binding
affinity (see the five peptides illustrated on the right of Figure 5A).
This suggested that the C-terminal domain was permissive for
binding to the ATM-2 peptide. We found that the NKX3.1 C-ter-
minal domain had a significant influence on ATM binding and
also on the functional interaction between NKX3.1 and ATM.
Loss of the single C-terminal tryptophan of NKX3.1 markedly
diminished ATM binding, and deletion of 225–234 abrogated
binding (Figure S2A). Interestingly, restoration of tryptophan to
NKX3.1(1–224) restored the ability to bind ATM-2, suggesting
that the C-terminal tryptophan played an important role in facili-
tating ATM binding (Figure S2B). Loss of the C-terminal domainabrogated the effect of NKX3.1 on ATM activation by the MRN
complex (Figure S2C), in contrast to the effect seen with the
full-length NKX3.1 (Figure 2E). However, the NKX3.1(1–183) pep-
tide was fully competent to enhance ATM activation by H2O2
(Figure S2D). Thus, we were able to discriminate between the
stronger effect of NKX3.1 on ATM activation by H2O2 and the
effect on ATM activation by the MRN complex by deletion anal-
ysis of NKX3.1.
Since we had demonstrated that (S/T)Q phosphorylation was
important for NKX3.1 turnover after DNA damage, and that ATM
bound to the homeodomain between the two TQ sites, we next
demonstrated that both homeodomain T(134)Q and T(166)Q
dipeptides are in fact phosphorylated by ATM. As a first step,
we engineered a compound mutation of each of two of all
three candidate ATM phosphorylation sites, S48, T134, and
T166. Each of these amino acids in NKX3.1 precedes a Q, thus
providing SQ or TQ sites preferred as targets for ATM phosphor-
ylation. Whereas loss of S48 did not affect (S/T)Q phosphoryla-
tion after DNA damage, the compound mutation T134,166A
abrogated (S/T)Q phosphorylation of NKX3.1 (Figure 5C). The
timing of TQ dipeptide phosphorylation that is abrogated by
T134A/T166A was consistent with the result shown in Figure 4A,
such that TQ phosphorylation was seen at 30 min predominantly
at T134 and at 60 min at both T134 and T166 (Figure 5D).Cell Reports 4, 516–529, August 15, 2013 ª2013 The Authors 521
Figure 5. ATM Binding Domains in NKX3.1
(A) Glutathione-bead-bound GST-ATM-2 peptide was incubated with cellular extract of 293T cells that had been transfected with MYC-NKX3.1 constructs as
shown at the top of the panel. Bound MYC-NKX3.1 peptides were detected by immunoblotting.
(B) The same experiment as in (A), but with constructs containing deletions of the NKX3.1 homeodomain.
(C) LNCaP cells transfected withMYC-NKX3.1 constructs preloaded with BrdU and pretreatedwith Hoechst 33258 dye and bortezomib were harvested 1 hr after
10 mJ/cm2 UV irradiation. Cell lysates were subjected to immunoprecipitation with MYC antibody and then analyzed by immunoblotting.
(legend continued on next page)
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Moreover, binding of NKX3.1 to ATM was required for degrada-
tion, as missense mutation of the terminal NKX3.1 tryptophan
abrogated TQ phosphorylation and prolonged the half-life of
NKX3.1 after DNA damage (Figure 5E, left panels). The effect
on both TQ phosphorylation and the NKX3.1 half-life of the
NKX3.1(W234A) missense mutation was the same as the
effect of changing both T134 and T166 to alanines (Figure 5E).
Therefore, binding NKX3.1 to ATM was required for both sub-
strate interaction and DNA-damage-induced turnover, implying
that ATM played a role in modulating the effect of NKX3.1
after DNA damage. Lastly, phosphorylation of NKX3.1 at the
homeodomain TQ sites was shown to be important for DNA-
damage-induced ubiquitination of NKX3.1, demonstrating that
ATM phosphorylation resulted in proteasomal degradation of
NKX3.1 during the first hour after DNA damage (Figure 5F).
Even though threonines 134 and 166 were substrate sites for
ATM kinase, we also wanted to examine how these sites influ-
ence the effect of NKX3.1 on ATM function. We restored
NKX3.1 expression in LNCaP(si471) cells with either wild-type
or NKX3.1(T134,166A) expression constructs. The loss of both
threonines resulted in a 40% reduction in the intensity of
gH2AX to a DNA damage site (Figure S3A) and delayed activa-
tion of ATM phosphorylation (Figure S3B). We should point out
that the effect of T/A mutations at these two sites may have
changed the homeodomain sufficiently to compromise binding
with ATM, and the attenuation of NKX3.1’s effect on ATM
activity may not have been due to the loss of the substrate target
sites per se.
Tyrosine Phosphorylation of NKX3.1
We showed that NKX3.1 underwent tyrosine phosphorylation
within minutes of DNA damage (Figure 4A). To determine
whether tyrosine phosphorylation of NKX3.1 was important to
initiate its participation in the DNA damage response, we first
identified the target tyrosine phosphorylation site(s). Using
comprehensive site-directed mutagenesis of all tyrosines in
NKX3.1, we found that Y222 in the C-terminal domain was the
site for tyrosine phosphorylation after DNA damage. In partic-
ular, mutation of tyrosine 222 to phenylalanine (Y222F) was as
effective as mutation of all NKX3.1 tyrosines to phenylalanine
residues in attenuating the effect of DNA damage on degradation
of NKX3.1. Conversely, an NKX3.1 protein with native Y222 but
all other tyrosines mutated to phenylalanine retained the effect
of DNA damage on NKX3.1 protein levels (Figure 6A). The impor-
tance of Y222 in the response of NKX3.1 to DNA damage was
further demonstrated by the loss of DNA-damage-induced tyro-
sine phosphorylation of NKX3.1 when tyrosine 222 was mutated
to phenylalanine, and by the preservation of tyrosine phosphor-(D) Experiment performed as in (C), but with cells harvested at the indicated time
(E) 293T cells expressing MYC-NKX3.1 constructs were preincubated with BrdU
irradiation. Cells were harvested 60 min after irradiation and subjected to immun
show levels of NKX3.1 after irradiation from cultures that were not treated with b
(F) LNCaP cells were cotransfected with expression constructs for a fusion HIS-ub
166A). They were then preloaded with BrdU and pretreated with Hoechst 3325
irradiation. Cells were harvested 4 hr after UV exposure. A His Bind Purification K
were resolved by SDS-PAGE and immunoblotted with polyclonal anti-MYC antib
See also Figures S2 and S3.ylation in the NKX3.1 derivative in which all tyrosines except
Y222 were mutated to phenylalanine (Figure 6B). Also, Y222
was shown to be required for optimal NKX3.1 binding with
ATM. In physical association experiments with GST-ATM-2,
the preservation of only Y222 resulted in the same degree of
binding to ATM as the native NKX3.1 protein, whereas loss of
only Y222 diminished NKX3.1 association with the ATM peptide
after irradiation (Figure 6C). Loss of Y222 reduced the associa-
tion of NKX3.1 with endogenous ATM in 293T cells, comparable
to the effect of loss of the two threonine phosphorylation sites in
the homeodomain. The same DNA damage conditions used
for 293T cells caused association of endogenous NKX3.1 and
ATM in LNCaP cells (Figure 6D).
Importantly, tyrosine 222 phosphorylation had a functional role
in the DNA damage response. Tyrosine 222 was necessary for
efficient activation of ATM kinase by NKX3.1. Exogenous
expression of NKX3.1, but not NKX3.1(Y222F), in 293T cells
activated ATM phosphorylation of P53 (Figure 6E). Moreover,
compared with native NKX3.1, NKX3.1(Y222F) expression in
LNCaP(si471) cells was accompanied by marked attenuation in
recruitment of gH2AX to a DNA damage site (Figure 6F). Having
previously shown that NKX3.1 expression enhanced colony-
forming ability after DNA damage (Bowen and Gelmann, 2010),
we compared the capacities of NKX3.1(Y222F) and the wild-
type protein to affect cell survival in a colony-formation assay.
We engineered 293T cells to express NKX3.1 along with a
GST coselectable marker. Colony formation was assayed
after two different doses of UV in BrdU-loaded and Hoechst
33258 dye-treated cells and in cells exposed to 5 and 10 Gy
g-irradiation. In each instance, NKX3.1(Y222F) was attenuated
compared with the wild-type in enhancing cell survival (Fig-
ure 6G). In LNCaP prostate cancer cells, we also observed that
NKX3.1(Y222F) was attenuated in its ability to affect cell survival
after DNA damage induced both by UV and by g-irradiation
(Figure S4). Therefore, Y222 phosphorylation of NKX3.1 after
DNA damage facilitated the interaction and activation of
ATM, demonstrating that NKX3.1 is a recipient of signal trans-
duction early in the DNA damage response and potentiates
ATM activation.
An important consequence of the role of NKX3.1 in DNA repair
is the effect of the protein on TMPRSS2-ERG rearrangement
(C.B. and E.P.G., unpublished data). NKX3.1 can be found at
the break points in the ERG gene that recombine with TMPRSS2
to form the fusion transcripts found in the majority of prostate
cancers (Tomlins et al., 2005). Reduced levels of NKX3.1 predis-
pose cells to TMPRSS2-ERG rearrangement that is mediated by
androgen receptor (Mani et al., 2009; Figure 6H, left panel).
Moreover, NKX3.1 recruits ATM to a major locus of ERG genepoints.
, Hoechst 33258 dye, and bortezomib (upper panels) prior to 10 mJ/cm2 UV
oprecipitation with MYC antibody and then immunoblotting. The lower panels
ortezomib.
iquitin peptide and either epitope taggedMYC-NKX3.1 or MYC-NKX3.1 (T134/
8 dye ± 100 nM bortezomib for 1 hr, followed by exposure to 10 mJ/cm2 UV
it (Novagen) was used to assess the ubiquitination of NKX3.1. Eluted proteins
ody.
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Figure 6. Tyrosine Phosphorylation of NKX3.1 Induced by DNA Damage
(A) 293Tcells transfectedwith Flag-ATMexpression plasmids andMYC-NKX3.1 expressionconstructswere preincubatedwithBrdUandHoechst 33258dyeprior
to 10mJ/cm2UV irradiation.Cellswere harvested 30min after irradiation. Lysateswere subjected to immunoprecipitationwithMYCantibody and immunoblotting.
(B) LNCaP cells were transfected with MYC-NKX3.1 constructs. Cells were preloaded with BrdU, pretreated with Hoechst 33258 dye and 100 nM bortezomib,
and harvested 5 min after exposure to 10 mJ/cm2 UV irradiation. The cell lysates were subjected to immunoprecipitation with MYC antibody and immunoblotted
with either antibody to MYC or phosphotyrosine.
(legend continued on next page)
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Figure 7. Proposed Model for NKX3.1 Interaction with ATM
Within minutes of DNA damage, ATM is phosphorylated on S1981 and NKX3.1
on tyrosine 222. Both posttranslational modifications facilitate binding of the
two proteins, which results in activation of ATM activity and accumulation of
pATM at sites of DNA damage. By 30 min, ATM phosphorylates NKX3.1 on
T166 and then T134, resulting in NKX3.1 ubiquitination and degradation re-
sulting from an apparent regulatory interaction.fusion (Lin et al., 2009), and that recruitment is attenuated in
LNCaP(si471) cells (Figure 6H, right panel). This result and re-
sults yet to be published demonstrate that the effect of NKX3.1
on the DNA repair response plays a role in the earliest steps
of prostate carcinogenesis by influencing the propensity for
TMPRSS2-ERG rearrangement.
DISCUSSION
Clinical prostate cancer occurrence rises more sharply (>7-fold)
than any other cancer during the last three decades of life. In the
aging prostate and the inflamed gland, two conditions that pre-
dispose to prostate cancer, NKX3.1 is downregulated (Bethel
et al., 2006; Khalili et al., 2010). NKX3.1 modulates the response
to DNA damage (Bowen and Gelmann, 2010) by interacting and
upregulating ATM activation, as we have now shown. The effect
of NKX3.1 on the DNA repair process has important implications(C) GST-ATM-2 peptide bound to glutathione beads was incubated with cellular e
and peptide-bound NKX3.1 were detected by immunoblotting with anti-MYC anti
(D) 293T were transfected with MYC-NKX3.1 expression constructs. Cells were
tezomib for 30 min prior to exposure to 10 mJ/cm2 UV irradiation. Lysates were su
immunoblotted with NKX3.1 antiserum or monoclonal ATM antibody (GeneTex).
(E) 293T cells expressing MYC-NKX3.1 constructs by transient transfection were
The cells were collected at the indicated times after irradiation and processed fo
(F) LNCaP(si471) cells were transiently transfected with MYC-NKX3.1 constructs a
LMI (speed: 20; focus: 63; power: 36) at the indicated times. Cells were fixed a
accumulation was measured with ImageJ software by counting 30 cells per time
(G) 293T cells were transfected with the indicated NKX3.1 expression constructs a
pretreated with Hoechst 33258 dye. Cells were sorted by GFPwith a BD FACSAria
to either 10 mJ/cm2 UV or 10 Gy g-irradiation. Colony formation was counted 7–
normalization to untreated control samples. The inset immunoblot demonstrates
(H) LNCaP(siLuc) and LNCaP(si471) cells were synchronized with 5 mM a-amanit
100 mM etoposide. Cells were harvested after 24 hr. FISH analysis was done to
analyzed and the data are derived from three independent experiments. Right pa
site (Lin et al., 2009). Extracts of cells treated with either EtOH or 100 mM DHT plu
Cruz). ATM binding at the break point was quantitated by ImageJ software and
See also Figure S4.for the etiology, prevention, and treatment of prostate cancer. As
an early event in primary prostate cancer and PIN, NKX3.1 hap-
loinsufficiency and methylation represent major contributors to
prostate carcinogenesis at this early preinvasive stage (Asatiani
et al., 2005; Bethel et al., 2006). Furthermore, early loss of
NKX3.1 and downregulation of NKX3.1 protein expression con-
tribute to the susceptibility of prostate epithelial cells to oxidative
damage, both in human prostate cancer (Nelson et al., 2003) and
in mouse models (Ouyang et al., 2005). These effects are exac-
erbated by decreased expression of GSTP1 (Lin et al., 2001)
and also may be affected by mutations in the macrophage
scavenger receptor 1 (Nupponen et al., 2004; Seppa¨la¨ et al.,
2003; Wang et al., 2003). Our recent studies have now estab-
lished a probative link between NKX3.1 loss and the DNA dam-
age response (Bowen and Gelmann, 2010), which may help
explain its functions in tumor suppression.
From the data in this paper, we have derived amodel of NKX3.l
action in response to DNA damage (Figure 7). Within 5 min of
DNA damage, NKX3.1 undergoes phosphorylation at tyrosine
222 by an as yet unidentified kinase. Tyrosine phosphorylation
is required for NKX3.1 to associate with ATM in the region
between amino acids 431 and 490. NKX3.1 binds to ATM via
the homeodomain and also via the C-terminal domain, and bind-
ing is enhanced by a C-terminal tryptophan. NKX3.1 binding to
ATM is favored by early phosphorylation of ATM, as shown at
the 10 min time point in Figure 5C. Therefore, we suggest that
NKX3.1 binding to ATM is modulated by ATM phosphorylation
that occurs at many sites during the DNA damage response.
By 30 min, ATM initiated phosphorylation of two threonines
that flank the ATM binding site in the NKX3.1 homeodomain.
Threonine 166 appears to be phosphorylated first, followed by
threonine 134. Phosphorylation at these two sites mediates
ubiquitination and DNA-damage-induced proteasomal degrada-
tion of NKX3.1, thus terminating NKX3.1’s involvement in the
damage response.
Based on our recent findings, we propose that a principal
mechanism by which NKX3.1 loss affects prostate carcino-
genesis is via impaired DNA damage signaling. Many of the
histologic and pathologic changes in the aging prostate arextract of 293T cells transfected with MYC-NKX3.1 constructs as shown. Input
body. At the right is shown the negative control using GST not fused to ATM-2.
preloaded with BrdU and pretreated with Hoechst 33258 dye and 10 nM bor-
bjected to immunoprecipitation with 2 mg anti-ATM antiserum (Santa Cruz) and
LNCaP cells were similarly treated without transfection.
pretreated with BrdU and Hoechst 33258 dye prior to 10 mJ/cm2 UV exposure.
r immunoblotting.
s shown. Cells were pretreated with BrdU and Hoechst 33258 dye followed by
nd stained with gH2AX monoclonal antibody. The relative intensity of gH2AX
point.
nd the selectable GFP expression plasmid. Cells were preloadedwith BrdU and
Cell Sorter and plated on poly-L-lysine-coated dishes for 4 hr before exposure
10 days after treatment. The percentage of colony formation was obtained by
equivalent expression of transgenes in the transfected cells.
in for 2 hr and exposed to EtOH or 100 nM DHT for 1 hr and then treated with
identify cells with TMPRSS2-ERG rearrangements. One hundred cells were
nel: data from a ChIP assay performed with primers flanking the ERG IV break
s 100 mM etoposide for 4 hr were subjected to ChIP with ATM antibody (Santa
expressed as a percentage of input.
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accompanied by decreased NKX3.1 expression, thus predis-
posing to DNA damage and carcinogenesis. Even in the inflamed
or aging prostate, NKX3.1 loss is mediated by inflammatory
cytokines that induce phosphorylation of NKX3.1, leading to
ubiquitination and proteasomal degradation, and thus short-
ening the protein’s half-life (Markowski et al., 2008). The same
inflammatory insult also increases the chance of mutation by
oxidative DNA damage (Nelson et al., 2003; Ouyang et al.,
2005). Oxidative damage is mediated to a large part by the for-
mation of 8-oxo-guanine adducts that can cause mutational
nucleotide transitions if they are not repaired (Grollman and
Moriya, 1993). Repair of 8-oxo-guanine adducts is accom-
plished by base excision repair, which has been shown to be
affected by ATM activation and CHK2 phosphorylation (Chou
et al., 2008; Parlanti et al., 2002; Pascucci et al., 2002). ATM is
likely to play a critical role in the cell’s response to oxidative
DNA damage, since the enzyme is activated by oxidation alone
in the absence of damaged DNA (Guo et al., 2010b). We show
in this paper that NKX3.1 augments ATM activation more pro-
foundly in response to oxidation than to the presence of
damaged DNA. Thus, an important function of NKX3.1 is to
accelerate and amplify ATM activation in the prostate, a tissue
that is subject to remarkably high levels of oxidative stress due
to inflammation.
Our findings are also relevant to stem cell biology because
the expression of NKX3.1 in the prostate stem cells known as
castration-resistant Nkx3-1-expressing cells (CARNS) may in-
crease stem cell survival by enhancing the cell’s ability to repair
DNA damage. The role of NKX3.1 in the stem cell may be further
expanded to include cooperation with androgen receptor tran-
scriptional activation (He et al., 2010). In fact, NKX3.1 often
colocalizes with androgen receptor for transcriptional activation
and helps to drive a survival program in prostate epithelial cells,
suggesting yet another mechanism by which NKX3.1 expression
may be very important for stem cells (Tan et al., 2012). The role of
NKX3.1 in murine prostate stem cells may also be relevant for
humans, as CARN-like cells have now been described in the
human prostate (Germann et al., 2012).
NKX3.1 is expressed in very few human tissues beyond the
prostate gland and in no tissues where its expression is present
in the majority of cells (Bowen et al., 2000). Therefore, the effect
of NKX3.1 on the DNA damage response and on cellular survival
after DNA damage is largely specific to the prostate. NKX3.1 also
activates topoisomerase I, and we have shown in gene-targeted
mice that the effect of Nkx3.1 on topoisomerase I is localized
only to the prostate gland (Bowen et al., 2007). Topoisomerase
I is a ubiquitous DNA unwinding enzyme that is highly conserved
in evolution and has been shown, among itsmany effects, to play
a role in the cell’s susceptibility to DNA damage (Miao et al.,
2007). Thus, NKX3.1 enhances the activity of two key enzymes
in the DNA repair process, affecting both the damage response
via ATM and the capability for DNA repair via topoisomerase I.
We speculate that our findings suggest a biological explana-
tion for differences observed in the sensitivities of different tissue
types to g-irradiation, and differences in their abilities to function
after irradiation. Inherent in our findings is the implication that
prostate-specific expression of NKX3.1 translates into tissue-
specific effects on the DNA repair process. Thus, our work pro-526 Cell Reports 4, 516–529, August 15, 2013 ª2013 The Authorsvides insight into the molecular mechanisms of tissue-specific
differences of DNA repair, and perhaps radiation sensitivity.
The efficacy of radiation therapy for the treatment of prostate
cancer, as well as long-standing observations that there is a
dose-response curve for radiation to provide long-term disease
control, underscore the importance of findingways to affect DNA
repair pathways in prostate cancer cells (Pollack et al., 2000;
Pollack and Zagars, 1997).EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, and Reagents
LNCaP, 293T, and PC-3 cell culture and transfection, as well as the LNCaP
derivative lines with NKX3.1 knockdown, LNCaP(siLuc), and LNCaP(si471)
have been previously described (Bowen and Gelmann, 2010). ATM and ATR
inhibitors Ku55933 and caffeine were purchased from Sigma. Cycloheximide
was obtained from Sigma. Control inhibitory RNA and siATM SMARTpool
siRNAs were obtained fromDharmacon. 293T cells were engineered for stable
incorporation of pHPRT-DP-GFP (SceGFP) plasmid (from Maria Jasin) with
lipofectamine 2000 (Rouet et al., 1994). The cells were transfected with
pcDNA3-NKX3.1 and pCBASce, an I-SceI expression vector, for 24 hr. ChIP
was performed with 2 mg of anti-NKX3.1 antibody (goat; Santa Cruz). The
PCR primers were GFP 1F:50- CGT CCA GGA GCG CAC CAT CTT CTT-30
and GFP 1R:50-ATC GCG CTT CTC GTT GGG GTC TTT-30.Constructs
GST-ATM fusion peptide expression constructswere provided byK.K. Khanna
(University of Queensland, Brisbane, Australia). The GST-P53 expression vec-
tor was obtained from T.T.P. Wild-type and KD Flag-ATM vectors were pro-
vided by M.B. Kastan (St. Jude Children’s Research Hospital, Memphis, TN,
USA). GST-ATM2 deletion constructs were produced using the QuikChange
site-directed mutagenesis kit (Stratagene). Flag-ATM(D431-490) was gener-
ated with the QuikChange XL site-directed mutagenesis kit (Stratagene) with
a modified protocol, with the PCR extension time at 1.5 min/kb. pcDNA3-
NKX3.1 full-length and truncated constructs was produced by inserting PCR
fragments of NKX3.1 into pcDNA3 vector at EcoRI and XhoI sites. MYC-
NKX3.1 HD and C terminus deletion constructs were made by introducing
NKX3.1 PCR fragments into pCMV-MYC vector at EcoRI and Xho I sites. The
MYC-NKX3.1 point mutant or combined point and deletion mutant constructs
were generated either by mutation with the QuikChange site-directed muta-
genesis kit or by inserting modified PCR fragments into pCMV-MYC vector.
GST-p53 substrate (pTP317; 1–102 aa) was provided by T.T.P.Induction of DNA Damage
In most experiments, double-stranded DNA breaks were introduced by irradi-
ating cells with 20 mJ/cm2 after 48 hr of preloading with 10 mM BrdU and a
30 min treatment with 10 mg/ml Hoechst 33258 dye (Limoli and Ward, 1993).
This approach has been used by other groups and validated as a method to
induce double-stranded DNA breaks (Huang et al., 2004; Khalil et al., 2011).
Key experiments were repeated with g-irradiation. We previously showed
that NKX3.1 has affects equal to the DNA damage response induced by
g-irradiation, mitomycin C, and UV without cell sensitization (Bowen and Gel-
mann, 2010).Protein Purification
His-NKX3.1 was prepared as previously described (Bowen et al., 2007). The
MRN complex and GST-p53 substrate were purified as previously described
(Bhaskara et al., 2007; Lee and Paull, 2004). Dimeric ATM was made by tran-
sient transfection of expression constructs into HEK 293T cells using calcium
phosphate and purified as previously described (Lee and Paull, 2006). Protein
concentrations were determined by quantification of protein preparations with
standards on colloidal Coomassie-stained SDS-PAGE gels using the Odyssey
system (Li-Cor).
Immunofluorescence and LMI
Cells were fixed and permeabilized inCSKbuffer (10mMPIPES, 100mMNaCl,
300 mM sucrose, 3 mMMaCl2, and 1 mM EGTA) containing 4% formaldehyde
and 0.1% Triton X-100 for 15 min, and LMI was performed as previously
described (Bowen and Gelmann, 2010). Cells were sensitized with 10 mg/ml
of Hoechst dye 33258 for 30 min. Prior to irradiation, cells were washed twice
with culture medium. Irradiation was performed through a 403 objective with a
cut speed ranging from 10% to 40%and power output of 45%, focus 61. Oper-
ation was assisted by the PALMRobo-Software supplied by themanufacturer.
Cells were fixed and permeabilized inCSKbuffer (10mMPIPES, 100mMNaCl,
300 mM sucrose, 3 mMMgCl2, 1 mM EGTA) containing 4% formaldehyde and
0.1% Triton X-100 for 15 min. The following procedure was then performed as
previously described (Bowen andGelmann, 2010): primary gH2AXandNKX3.1
antibodies were employed at dilutions of 1:1,000 or 1:200, respectively, and
samples were incubated with secondary antibodies gH2AX (FITC, goat anti-
mouse immunoglobulin G [IgG]; Vector) and NKX3.1 (Alexa Fluor-568, goat
anti-rabbit IgG; Molecular Probes).
Immunoprecipitation and Immunoblotting
Cell lysates were prepared with RIPA buffer containing protease inhibitors
(cOmplete, Mini; Roche) and with phosphatase inhibitors when appropriate
(PhosStop; Roche). Immunoprecipitation was done with 500 mg of cell lysate
and 2 mg of antibody followed by the use of the Catch and Release Immuno-
precipitation kit (Millipore) or protein A/G agarose (Calbiochem). Proteins
were resolved by SDS-PAGE, transferred to a nitrocellulosemembrane, immu-
noblotted, and detected with SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific) or SuperSignal West Dura Extended Duration
Substrate (Thermo Scientific). The antibodies used were as follows: gH2AX
(Upstate), pATM-S1981 (Rockland), ATM (GeneTex), ATR (C-19; Santa
Cruz), b-actin (Sigma), H2AX antiserum (Abcam), phospho-P53(S15) (Cell
Signaling), Flag (Sigma), p(S/T)Q (Cell Signaling), and phosphotyrosine and
MYC (Santa Cruz).
GST Pull-Down Assay
GST fusion peptides were expressed in BL21 cells after induction by 0.2 mM
isopropyl b-D-1-thiogalactopyranoside for 2–3 hr. Cells were harvested and
resuspended in STE buffer (10 mM Tris [pH 8.0], 150 mM NaCl, and 1 mM
EDTA), followed by addition of freshly prepared lysozyme and then incubation
on ice for 15 min. Just before sonication, 1 M dithiothreitol (DTT) and 10% sar-
kosyl were added. The lysate was cleared by centrifugation, incubated with
10% Triton X-100 in STE buffer for 30 min, and equilibrated glutathione beads.
Where indicated, 100–250 ng of purified His-NKX3.1 or 250–500 mg of LNCaP
cell lysate was incubated with agarose-bound GST-fusion peptides for 1 hr at
room temperature. Dissociation was achieved with SDS, and proteins were
resolved on SDS-PAGE and detected by immunoblotting.
ATM Kinase Assay
FLAG-tagged ATM and KD ATM constructs were expressed by transfection.
Cells were lysed with TGN buffer (50 mM Tris [pH7.4], 150 mM NaCl, 10%
glycerol, 0.2% Tween 20, 0.2% NP40, and 1 mM DTT), protease inhibitors,
and phosphatase inhibitors. Epitope-tagged proteins were isolated from
100 mg of lysate with 30 ml of anti-FLAG M2 agarose (Sigma-Aldrich) in TGN
buffer for 1 hr at 25, washed three times with TGN containing 0.5 M LiCl,
and then washed once with kinase buffer. GST-P53 fusion proteins were
expressed in Escherichia coli BL2 and affinity purified. ATM kinase assays
were done in kinase buffer (10 mM HEPES [pH7.5], 50 mM NaCl, 10 mM
MgCl2, 10% glycerol, and 500 mM ATP). Agarose-bound Flag-ATM and His-
NKX3.1 were mixed at 25C for 30 min, and then 1 mg of GST-P53 was added
and incubated at 30C for 60 min in a volume of 30 ml. GST-P53 was resolved
by SDS-PAGE, followed by immunoblotting with monoclonal phospho-
P53(S15) and NKX3.1 antiserum.
In Vitro ATM Kinase Assay
ATM kinase assays contained 0.7 nM dimeric ATM, 5 nM GST-p53 substrate,
1.5 nM MRN complex, 10 ng DNA, and varying amounts of NKX3.1 as indi-
cated in the figure legends. Kinase assays were performed in kinase buffer
(50 mM HEPES [pH 7.5], 50 mM potassium chloride, 5 mM magnesium chlo-ride, and 10% glycerol, 1 mM ATP, and 1 mM DTT) for 90 min at 30C in a
volume of 40 ml as described previously (Lee and Paull, 2005). In experiments
where H2O2 was used, no additional DTT was added to the reactions and ATM
kinase assays were performed with 40 nM P53 and 0.7 mMH2O2 as previously
described (Guo et al., 2010b). Phosphorylated p53 (ser15) was detected as
previously described (Lee and Paull, 2004) using phospho-specific antibody
from Calbiochem (PC461).
Fluorescence In Situ Hybridization
LNCaP(siLuc) and LNCaP(si471) cells were cultured in 35mm dishes in phenol
red-free Iscove’s modified Eagle’s medium (IMEM) containing 10% fetal
bovine serum (FBS). To increase the frequency of chromosomal rearrange-
ment, cells were treated with 100 mM etoposide after exposure to 100 mM
dihydrotestosterone (DHT). Interphase cells were prepared for fluorescence
in situ hybridization (FISH) analysis by 0.075 M KCl hypotonic treatment at
37C for 30 min and fixed with 3:1 methanol:glacial acetic acid at 4C.
FISH was performed 24 hr after fixation using BAC DNA probes labeled with
biotin (Biotin-Nick Translation Mix; Roche) and digoxigenin (Dig-Nick Transla-
tion Mix; Roche). BAC DNA plasmids (BACPAC Resources Center, Children’s
Hospital, Oakland Research Institute) were amplified and purified using the
QIAGEN Plasmid Midi Kit. To assay TMNPRSS2-ERG rearrangements, we
used an ERG split probe that contains 50ERG (DIG) (RP11-95I21) and 30 ERG
(BIO) (RP11-476D17). Prior to hybridization, the slides were pretreated with
23 SSC at 37C for 15 min and then with 23 SSC at 75C for 5 min, followed
by passage through sequential washes of 70%, 80%, 95%, and 100%ethanol.
Probes and slides were denatured at 75C for 5 min separately with slides in
prewarmed 70% formamide in 23 SSC. Hybridization was allowed to proceed
at 37C overnight. Posthybridization washes were performed in prewarmed
50% formamide in 23 SSC at 37 three times, followed sequentially by two
washes in prewarmed 0.53 SSC/0.3% NP-40 solution, at 60C for 2 min,
one wash in 23 SSC/0.1% NP-40 at room temperature, and one wash in 13
PBS containing 0.1% Tween 20. Finally, the slides were incubated with
100 ml of blocking reagent (CAS block; ZYMED) with 1% goat serum 30 min
at 25C. FISH signals were detected with streptavidin Alexa Fluor 594 conju-
gate (Invitrogen) and anti-digoxigenin fluorescein antibodies (Roche) diluted
in blocking reagent for 30 min at 25C. Slides were counterstained with
DAPI in PBS and mounted in Antifade Mounting Medium (Molecular Clones).
Fluorescence images were captured with a 1003 objective on an Axiovert
wide-field microscope. Image analysis was done using ImageJ processing
software.
TMPRSS2-ERG ChIP
Cells were grown to 70% confluence in phenol-red-free modified IMEM sup-
plemented with 10% FBS, after which the medium was changed to IMEM
with 10% charcoal-stripped FBS (CCS) for 3 days. Following the addition of
100 nMDHT for 60min, cells were treated with 100 mMetoposide for 4 hr. Cells
were subjected to crosslinkingwith 0.75% formaldehyde at 25C for 8min with
agitation, the reaction was quenched with 125 mM glycine for 5 min, and the
cells then were rinsed with ice-cold PBS twice. To prepare crude nuclei, cells
were resuspended in hypotonic lysis buffer (20 mM Tris-HCl [pH 7.5], 10 mM
NaCl, and 3 mM MgCl2) with a protease inhibitor cocktail (Roche) on ice for
10 min. The nuclei were subjected to dounce homogenization with 20 strokes,
suspended in RIPA buffer, and sonicated at output level 4, 15 times for 10 sec
each at 1 min intervals on ice using a Micromix sonicator 3000. A ChIP assay
was performed with 50 mg of chromatin DNA per reaction. Supernatants were
collected and diluted 1:5 in buffer (1% Triton X-100, 2 mM EDTA, 150 mM
NaCl, and 20 mM Tris-HCl [pH 8.1]), and 1% chromatin was used as the input
sample. One milliliter of lysate was precleared with 10 mg sheared salmon
sperm DNA (Invitrogen), 10 ml serum, and protein A-sepharose (50 ml of 50%
slurry in 10 mM Tris-HCl [pH 8.1], 1 mM EDTA) for 1–2 hr at 4C. Immunopre-
cipitation was performed overnight at 4C with 2 mg antibody. After immuno-
precipitation, 30 ml of protein A-Sepharose, 10 mg of salmon sperm DNA,
and 10 ml of serum were added and the incubation was continued for 1–2 hr
at 4C. Precipitates were washed sequentially for 5 min each in TSE I (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH8.1], and 150 mM
NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH
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deoxycholate, 1 mM EDTA, and 10 mM Tris-HCl [pH 8.1]). Precipitates were
then washed twice with TE buffer. Chromatin was eluted twice with 1%
SDS, 0.1 M NaHCO3 for 15 min and then decrosslinked in 225 mM NaCl for
12 hr at 65C. The DNA was sequentially treated with RNase (50 mg/ml) at
37C for 30 min and then proteinase K (100 mg/ml) at 37C for 30 min, and
then purified over a QIAquick spin column (QIAGEN) per themanufacturer’s in-
structions. For quantitative PCR, 1 ml from a 40 ml DNA extraction was sub-
jected to 40–50 cycles of PCR amplification. The result was analyzed as
percent input after immunoprecipitation relative to the untreated control. The
following PCR primers were used: ERG ChIP IV f: 50-GAG GGA GAG GTG
CAA ATT AGA G-30 and ERG ChIP IV r: 50-GGC TGA AGG ACA GGG ATT
G-30.
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